Sangui Biotech International's Enterprise Value for the quarter that ended in Mar. 2023 was $1.14 Mil.
Sangui Biotech International's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.11 Mil. Sangui Biotech International's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2023 was -9.23%.
The historical rank and industry rank for Sangui Biotech International's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
SGBI's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.54 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Sangui Biotech International's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Sangui Biotech International Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Sangui Biotech International's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Sangui Biotech International Annual Data
Trend
Jun13
Jun14
Jun15
Jun16
Jun17
Jun18
Jun19
Jun20
Jun21
Jun22
Earnings Yield (Joel Greenblatt) %
-6.02
-18.35
-6.20
-3.95
-1.97
Sangui Biotech International Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Earnings Yield (Joel Greenblatt) %
-2.10
-1.97
0.40
-7.60
-9.23
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sangui Biotech International Earnings Yield (Joel Greenblatt) % Distribution
For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sangui Biotech International's Earnings Yield (Joel Greenblatt) % falls into.
Sangui Biotech International Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Sangui Biotech Internationals Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2022 is calculated as
Sangui Biotech International's EBIT for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.
Sangui Biotech International (OTCPK:SGBI) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Sangui Biotech International Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Sangui Biotech International's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Sangui Biotech International (Sangui Biotech International) Business Description
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGBI has been successfully added to your 